220 related articles for article (PubMed ID: 18309713)
1. Increased level of urinary nitric oxide metabolites in leprosy patients during type 2 reactions and decreased after antireactional therapy.
Mohanty KK; Gupta M; Girdhar BK; Girdhar A; Chakma JK; Sengupta U
Lepr Rev; 2007 Dec; 78(4):386-90. PubMed ID: 18309713
[TBL] [Abstract][Full Text] [Related]
2. Serum zinc/copper ratio in subtypes of leprosy and effect of oral zinc therapy on reactional states.
George J; Bhatia VN; Balakrishnan S; Ramu G
Int J Lepr Other Mycobact Dis; 1991 Mar; 59(1):20-4. PubMed ID: 2030313
[TBL] [Abstract][Full Text] [Related]
3. Low serum HDL-cholesterol is associated with raised tumor necrosis factor-alpha during ENL reactions.
Memon RA; Kifayet A; Shahid F; Lateef A; Chiang J; Hussain R
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):1-11. PubMed ID: 9207748
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M; Berhe D
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
[TBL] [Abstract][Full Text] [Related]
5. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India.
Pocaterra L; Jain S; Reddy R; Muzaffarullah S; Torres O; Suneetha S; Lockwood DN
Am J Trop Med Hyg; 2006 May; 74(5):868-79. PubMed ID: 16687695
[TBL] [Abstract][Full Text] [Related]
6. High dose prednisolone treatment of leprosy patients undergoing reactions is associated with a rapid decrease in urinary nitric oxide metabolites and clinical improvement.
Schön T; Leekassa R; Gebre N; Sundqvist T; Bizuneh E; Britton S
Lepr Rev; 2000 Sep; 71(3):355-62. PubMed ID: 11105495
[TBL] [Abstract][Full Text] [Related]
7. Alterations in serum lipids in lepromatous leprosy patients with and without ENL reactions and their relationship to acute phase proteins.
Memon RA; Hussain R; Raynes JG; Lateff A; Chiang TJ
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):115-22. PubMed ID: 8690968
[TBL] [Abstract][Full Text] [Related]
8. Selective decrease of M. leprae-specific IgG1 and IgG3 antibodies in leprosy patients associated with ENL.
Kifayet A; Hussain R
Int J Lepr Other Mycobact Dis; 1996 Jun; 64(2):105-14. PubMed ID: 8690967
[TBL] [Abstract][Full Text] [Related]
9. [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
de Carsalade GY; Achirafi A; Flageul B
Acta Leprol; 2003; 12(3):117-22. PubMed ID: 15040702
[TBL] [Abstract][Full Text] [Related]
10. [Increase in nitric oxide concentrations in serum and mononuclear cell cultures from patients with Type II reaction state of Hansen's disease].
Rada E; Marzal M; Aranzazu N; Convit J
Invest Clin; 2003 Jun; 44(2):129-36. PubMed ID: 12815843
[TBL] [Abstract][Full Text] [Related]
11. Increased chitotriosidase activity in serum of leprosy patients: association with bacillary leprosy.
Iyer A; van Eijk M; Silva E; Hatta M; Faber W; Aerts JM; Das PK
Clin Immunol; 2009 Jun; 131(3):501-9. PubMed ID: 19307157
[TBL] [Abstract][Full Text] [Related]
12. Suppressor response in lepromatous leprosy patients: role of Leu 2a cells.
del Carmen Sasiain M; de la Barrera S; Ruibal-Ares B; Cardama JE; Gatti JC; de Bracco MM
Immunology; 1987 Jan; 60(1):13-8. PubMed ID: 2950048
[TBL] [Abstract][Full Text] [Related]
13. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
Rea TH; Sieling PA
Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for erythema nodosum leprosum.
Manandhar R; LeMaster JW; Roche PW
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
[TBL] [Abstract][Full Text] [Related]
15. ConA-induced suppressor cells in lepromatous leprosy patients during and after erythema nodosum leprosum.
Sasiain MC; Ruibal Ares B; Baliña LM; Valdez R; Bachmann AE
Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):321-7. PubMed ID: 6227570
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of reactions in leprosy.
Girdhar BK; Girdhar A; Chakma JK
Indian J Lepr; 2007; 79(2-3):121-34. PubMed ID: 18085170
[TBL] [Abstract][Full Text] [Related]
17. Serum proteome of leprosy patients undergoing erythema nodosum leprosum reaction: regulation of expression of the isoforms of haptoglobin.
Gupta N; Shankernarayan NP; Dharmalingam K
J Proteome Res; 2007 Sep; 6(9):3669-79. PubMed ID: 17658739
[TBL] [Abstract][Full Text] [Related]
18. Some unusual type 2 reactions in leprosy.
Ramesh V; Pahwa M
Int J Dermatol; 2010 Feb; 49(2):172-5. PubMed ID: 20465641
[TBL] [Abstract][Full Text] [Related]
19. The effects of prednisolone treatment on serological responses and lipid profiles in Ethiopian leprosy patients with Erythema Nodosum Leprosum reactions.
Negera E; Tilahun M; Bobosha K; Lambert SM; Walker SL; Spencer JS; Aseffa A; Dockrell HM; Lockwood DN
PLoS Negl Trop Dis; 2018 Dec; 12(12):e0007035. PubMed ID: 30592714
[TBL] [Abstract][Full Text] [Related]
20. The Effects of Prednisolone Treatment on Cytokine Expression in Patients with Erythema Nodosum Leprosum Reactions.
Negera E; Walker SL; Bobosha K; Bekele Y; Endale B; Tarekegn A; Abebe M; Aseffa A; Dockrell HM; Lockwood DN
Front Immunol; 2018; 9():189. PubMed ID: 29479352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
